These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 39241296)

  • 41. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.
    Locantore P; Novizio R; Corsello A; Paragliola RM; Pontecorvi A; Corsello SM
    Expert Opin Drug Discov; 2022 Feb; 17(2):101-107. PubMed ID: 34702125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
    Gao Q; Su J; Xiao F; Lin X; Yang J
    Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):853-861. PubMed ID: 34743497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
    Qin H; Yan H; Chen Y; Xu Q; Huang Z; Jiang W; Wang Z; Deng L; Zhang X; Zhang L; Yang N; Zeng L; Zhang Y
    BMC Cancer; 2024 Aug; 24(1):952. PubMed ID: 39097705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer - Case Report.
    Wang P; Matton L; Kebir F; Kerrou K; Dubois A; Lacave R; Cadranel J; Fallet V
    Clin Lung Cancer; 2022 Dec; 23(8):e568-e572. PubMed ID: 36127251
    [No Abstract]   [Full Text] [Related]  

  • 47. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated
    Solomon BJ; Zhou CC; Drilon A; Park K; Wolf J; Elamin Y; Davis HM; Soldatenkova V; Sashegyi A; Lin AB; Lin BK; F Loong HH; Novello S; Arriola E; Pérol M; Goto K; Santini FC
    Future Oncol; 2021 Mar; 17(7):763-773. PubMed ID: 33150799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
    Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
    Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
    Lee SH; Lee JK; Ahn MJ; Kim DW; Sun JM; Keam B; Kim TM; Heo DS; Ahn JS; Choi YL; Min HS; Jeon YK; Park K
    Ann Oncol; 2017 Feb; 28(2):292-297. PubMed ID: 27803005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation.
    Chunmao W; Haijie C; Zitong W; Zhi Y
    J Cardiothorac Surg; 2024 Oct; 19(1):554. PubMed ID: 39354540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
    Novello S; Califano R; Reinmuth N; Tamma A; Puri T
    Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
    Nadal E; Rifi N; Kane S; Mbacke S; Starkman L; Suero B; Le H; Samjoo IA
    Lung Cancer; 2024 Jun; 192():107816. PubMed ID: 38749072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
    Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Lung cancer treated abroad with receptor tyrosine kinase inhibitor].
    Eide IJZ; Brustugun OT
    Tidsskr Nor Laegeforen; 2021 Sep; 141():. PubMed ID: 34505490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer].
    Courtier B; Pierret T
    Bull Cancer; 2021 Jun; 108(6):562-563. PubMed ID: 34023064
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy of immune checkpoint inhibitor therapy in patients with
    Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
    Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
    Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
    Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.
    Lu C; Wei XW; Zhang YC; Chen ZH; Xu CR; Zheng MY; Yang JJ; Zhang XC; Zhou Q
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2987-2995. PubMed ID: 35838839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.